Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly.

Rapid progress in genomics and proteomics has provided a wealth of new targets for the pharmaceutical industry, even as many older targets still remain challenging for small-molecule drug discovery. Fragment-based lead discovery, in which leads are built progressively by expanding or combining small fragments, is a rapidly growing field that offers potential advantages over traditional lead-discovery processes. However, identifying and assembling the fragments themselves can be challenging. Here, we review the concept of site-directed ligand discovery, in which a covalent bond is used to stabilize the interaction between a low-affinity fragment and a target protein. We also describe how this technique can facilitate fragment-based lead discovery and help overcome some of the limitations of traditional screening methods.

[1]  Rapid screening by MALDI-TOF mass spectrometry to probe binding specificity at enzyme active sites. , 2003, Chemical communications.

[2]  W. Delano,et al.  In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.

[3]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[4]  J. Ermolieff,et al.  Protein tyrosine phosphatase 1B inhibitors for diabetes , 2002, Nature Reviews Drug Discovery.

[5]  Daniel A Erlanson,et al.  Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. , 2003, Journal of the American Chemical Society.

[6]  Michelle R. Arkin,et al.  Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Chemical approaches to the investigation of cellular systems. , 2002, Bioorganic & medicinal chemistry.

[8]  G. Rishton.  Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.

[9]  M. Randal,et al.  Potent small-molecule binding to a dynamic hot spot on IL-2. , 2003, Journal of the American Chemical Society.

[10]  B. L. Sibanda,et al.  Crystal structure of aspartate decarboxylase at 2.2 Å resolution provides evidence for an ester in protein self–processing , 1998, Nature Structural Biology.

[11]  Xiaoling Xie,et al.  Application of NMR screening in drug discovery. , 2003, Current topics in medicinal chemistry.

[12]  Matthew Bogyo,et al.  Chemical proteomics and its application to drug discovery. , 2003, Current opinion in biotechnology.

[13]  Michelle R Arkin,et al.  Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.

[14]  Michelle R Arkin,et al.  Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. , 2004, Journal of medicinal chemistry.

[15]  A. Eliseev,et al.  Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target. , 2003, Journal of medicinal chemistry.

[16]  P. Toogood.  Inhibition of protein-protein association by small molecules: approaches and progress. , 2002, Journal of medicinal chemistry.

[17]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[18]  Olof Ramström,et al.  Drug discovery by dynamic combinatorial libraries , 2002, Nature Reviews Drug Discovery.

[19]  Doris Riether,et al.  Reactivity of functional groups on the protein surface: development of epoxide probes for protein labeling. , 2003, Journal of the American Chemical Society.

[20]  H. Betz,et al.  AFFINITY LABELING OF CYSTEINE-MUTANTS EVIDENCES CONTACT RESIDUES IN MODELED RECEPTOR BINDING SITES , 2002, Journal of receptor and signal transduction research.

[21]  D. A. Campbell,et al.  Functional profiling of the proteome with affinity labels. , 2003, Current opinion in chemical biology.

[22]  Michelle R. Arkin,et al.  Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2 , 2002 .

[23]  A. Sharff,et al.  High-throughput crystallography to enhance drug discovery. , 2003, Current opinion in chemical biology.

[24]  C. Meares,et al.  Antibodies with infinite affinity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Stroud,et al.  Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Stuart J Rowan,et al.  Dynamic covalent chemistry. , 2002, Angewandte Chemie.

[27]  T. Nakayama,et al.  Selective irreversible inhibitors of aldose reductase. , 1992, Journal of medicinal chemistry.

[28]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[29]  W. Delano,et al.  Identification of potent and novel small-molecule inhibitors of caspase-3. , 2003, Bioorganic & medicinal chemistry letters.

[30]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.

[31]  D. Kohda,et al.  Peptide library approach with a disulfide tether to refine the Tom20 recognition motif in mitochondrial presequences. , 2003, Journal of molecular biology.

[32]  J. Lehn,et al.  Virtual combinatorial libraries: dynamic generation of molecular and supramolecular diversity by self-assembly. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Berg.  Modulation of protein-protein interactions with small organic molecules. , 2003, Angewandte Chemie.

[34]  Thomas Hughes,et al.  Inhibitors Tethered Near the Acetylcholinesterase Active Site Serve as Molecular Rulers of the Peripheral and Acylation Sites* , 2003, Journal of Biological Chemistry.

[35]  T. Muir.  Semisynthesis of proteins by expressed protein ligation. , 2003, Annual review of biochemistry.

[36]  P. Taylor,et al.  Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. , 2002, Angewandte Chemie.

[37]  G. Powers,et al.  Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2 , 1997 .

[38]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[39]  A. Eliseev,et al.  Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[41]  B. Cravatt,et al.  Chemical Strategies for Functional Proteomics* , 2002, Molecular & Cellular Proteomics.

[42]  H. Kolb,et al.  The growing impact of click chemistry on drug discovery. , 2003, Drug discovery today.

[43]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[44]  S. Homans.  NMR spectroscopy tools for structure-aided drug design. , 2004, Angewandte Chemie.

[45]  P. J. Belshaw,et al.  Selective inhibition of engineered receptors via proximity-accelerated alkylation. , 2003, Organic letters.

[46]  Daniel A Erlanson,et al.  Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. , 2002, Journal of medicinal chemistry.